Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 5-6/2020

25.10.2019 | original article

Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study

verfasst von: Peter Peichl, Rieke Alten, Mauro Galeazzi, Hanns-Martin Lorenz, Hubert Nüßlein, Federico Navarro, Yedid Elbez, Melanie Chartier, Roland Hackl, Christiane Rauch, Sean E Connolly

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 5-6/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

AbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was a 2-year international observational study of patients with moderate to severe rheumatoid arthritis.

Methods

Baseline characteristics, abatacept retention rates, and clinical outcomes were compared by treatment line in the Austrian cohort of ACTION.

Results

Of 100 patients enrolled in Austria, 98 (98.0%) were evaluable: 33/98 (33.7%) biologic naïve and 65/98 (66.3%) with ≥1 prior biologic failure. At baseline, biologic-naïve patients had shorter disease duration and lower concomitant corticosteroid use than biologic-failure patients. Overall crude abatacept retention rate was 60.5% and retention rate was higher in biologic-naïve (65.1%) versus biologic-failure (58.0%) patients. Good/moderate EULAR (European League Against Rheumatism) response rates were 85.7% in biologic-naïve and 100% in biologic-failure patients.

Conclusions

In the Austrian cohort of ACTION, overall abatacept retention at 2 years was high, with higher retention rates in patients receiving abatacept as an earlier treatment line. Good/moderate EULAR response rate was higher in biologic-failure than in biologic-naïve patients.
Literatur
1.
Zurück zum Zitat Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77. CrossRef Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77. CrossRef
2.
Zurück zum Zitat Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–22. CrossRef Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–22. CrossRef
3.
Zurück zum Zitat European Commission. The 2018 ageing report: economic and budgetary projections for the EU member states (2016–2070). 2018. European Commission. The 2018 ageing report: economic and budgetary projections for the EU member states (2016–2070). 2018.
4.
Zurück zum Zitat Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. CrossRef Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. CrossRef
5.
Zurück zum Zitat Smolen JS. Treat-to-target as an approach in inflammatory arthritis. Curr Opin Rheumatol. 2016;28(3):297–302. CrossRef Smolen JS. Treat-to-target as an approach in inflammatory arthritis. Curr Opin Rheumatol. 2016;28(3):297–302. CrossRef
6.
Zurück zum Zitat Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheumatol. 2009;61(5):560–8. CrossRef Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheumatol. 2009;61(5):560–8. CrossRef
9.
Zurück zum Zitat Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nusslein HG, et al. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD Open. 2017;3(2):e538. CrossRef Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nusslein HG, et al. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD Open. 2017;3(2):e538. CrossRef
10.
Zurück zum Zitat Nüßlein H, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2‑year, observational, prospective ACTION study. BMC Musculoskelet Disord. 2014;15(1):14. CrossRef Nüßlein H, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2‑year, observational, prospective ACTION study. BMC Musculoskelet Disord. 2014;15(1):14. CrossRef
11.
Zurück zum Zitat Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, et al. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol. 2016;34(3):489–99. PubMed Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, et al. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol. 2016;34(3):489–99. PubMed
12.
Zurück zum Zitat Prodinger B, Ndosi M, Nordenskiold U, Stamm T, Persson G, Andreasson I, et al. Rehabilitation provided to patients with rheumatoid arthritis: a comparison of three different rheumatology clinics in Austria, Sweden and the UK from the perspectives of patients and health professionals. J Rehabil Med. 2015;47(2):174–82. CrossRef Prodinger B, Ndosi M, Nordenskiold U, Stamm T, Persson G, Andreasson I, et al. Rehabilitation provided to patients with rheumatoid arthritis: a comparison of three different rheumatology clinics in Austria, Sweden and the UK from the perspectives of patients and health professionals. J Rehabil Med. 2015;47(2):174–82. CrossRef
13.
Zurück zum Zitat Puchner R, Hochreiter R, Pieringer H, Vavrovsky A. Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs. BMC Musculoskelet Disord. 2017;18(1):7. CrossRef Puchner R, Hochreiter R, Pieringer H, Vavrovsky A. Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs. BMC Musculoskelet Disord. 2017;18(1):7. CrossRef
14.
Zurück zum Zitat Alten R, Mariette X, Nuesslein H, Galeazzi M, Navarro F, Chartier M, et al. Abatacept retention rates and prognostic factors of retention in patients with rheumatoid arthritis: 2‑year results from the real-world ACTION study. Ann Rheum Dis. 2017;76(Suppl 2):FRI245. Alten R, Mariette X, Nuesslein H, Galeazzi M, Navarro F, Chartier M, et al. Abatacept retention rates and prognostic factors of retention in patients with rheumatoid arthritis: 2‑year results from the real-world ACTION study. Ann Rheum Dis. 2017;76(Suppl 2):FRI245.
15.
Zurück zum Zitat Alten R, Lorenz HM, Mariette X, Nüßlein H, Galeazzi M, Navarro F, et al. Abatacept retention rates, overall and by participating country, and prognostic factors of retention in patients with RA: 2‑year results from a real-world observational study. In: ACR/ARHP Annual Scientific Meeting, San Diego, CA, USA, November 4–8. 2017. p. Poster 1468. Alten R, Lorenz HM, Mariette X, Nüßlein H, Galeazzi M, Navarro F, et al. Abatacept retention rates, overall and by participating country, and prognostic factors of retention in patients with RA: 2‑year results from a real-world observational study. In: ACR/ARHP Annual Scientific Meeting, San Diego, CA, USA, November 4–8. 2017. p. Poster 1468.
18.
Zurück zum Zitat World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc. 1997;277(11):925–6. CrossRef World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc. 1997;277(11):925–6. CrossRef
19.
Zurück zum Zitat ICH Harmonised Tripartite Guideline. Guideline for good clinical practice. J Postgrad Med. 2001;47(3):199–203. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice. J Postgrad Med. 2001;47(3):199–203.
21.
Zurück zum Zitat Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumatol. 1988;31(3):315–24. CrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumatol. 1988;31(3):315–24. CrossRef
22.
Zurück zum Zitat Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745–57. CrossRef Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745–57. CrossRef
23.
Zurück zum Zitat Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404–13. CrossRef Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404–13. CrossRef
24.
Zurück zum Zitat Stamm TA, Reichardt B, Zwerina J, Ritschl V, Nell-Duxneuner V. Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011: a retrospective analysis of 72 % of the population. Wien Klin Wochenschr. 2018;130(7–8):230–7. CrossRef Stamm TA, Reichardt B, Zwerina J, Ritschl V, Nell-Duxneuner V. Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011: a retrospective analysis of 72 % of the population. Wien Klin Wochenschr. 2018;130(7–8):230–7. CrossRef
28.
Zurück zum Zitat Hifinger M, Hiligsmann M, Ramiro S, Watson V, Severens JL, Fautrel B, et al. Economic considerations and patients’ preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. Ann Rheum Dis. 2017;76(1):126–32. CrossRef Hifinger M, Hiligsmann M, Ramiro S, Watson V, Severens JL, Fautrel B, et al. Economic considerations and patients’ preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. Ann Rheum Dis. 2017;76(1):126–32. CrossRef
29.
Zurück zum Zitat Albrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, et al. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int. 2014;34(1):1–9. CrossRef Albrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, et al. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int. 2014;34(1):1–9. CrossRef
30.
Zurück zum Zitat Emery P, Solem C, Majer I, Cappelleri JC, Tarallo M. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. Rheumatol Int. 2015;35(11):1837–49. CrossRef Emery P, Solem C, Majer I, Cappelleri JC, Tarallo M. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. Rheumatol Int. 2015;35(11):1837–49. CrossRef
31.
Zurück zum Zitat Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206. CrossRef Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206. CrossRef
32.
Zurück zum Zitat Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? Ann Rheum Dis. 2014;73(11):2010–21. CrossRef Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? Ann Rheum Dis. 2014;73(11):2010–21. CrossRef
33.
Zurück zum Zitat Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, et al. The impact of patient heterogeneity and socio-economic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open. 2015;1:e40. CrossRef Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, et al. The impact of patient heterogeneity and socio-economic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open. 2015;1:e40. CrossRef
35.
Zurück zum Zitat Leon L, Rodriguez-Rodriguez L, Rosales Z, Gomez A, Lamas JR, Pato E, et al. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol. 2016;45(6):456–60. CrossRef Leon L, Rodriguez-Rodriguez L, Rosales Z, Gomez A, Lamas JR, Pato E, et al. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol. 2016;45(6):456–60. CrossRef
Metadaten
Titel
Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study
verfasst von
Peter Peichl
Rieke Alten
Mauro Galeazzi
Hanns-Martin Lorenz
Hubert Nüßlein
Federico Navarro
Yedid Elbez
Melanie Chartier
Roland Hackl
Christiane Rauch
Sean E Connolly
Publikationsdatum
25.10.2019
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 5-6/2020
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-019-00710-8

Weitere Artikel der Ausgabe 5-6/2020

Wiener Medizinische Wochenschrift 5-6/2020 Zur Ausgabe